Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 10/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28723226 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL28719243 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL11991177 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| Hydrochloric Acid SCHEMBL28723225 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL11701666 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL6374937 | 0.76 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL298053 | 0.72 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL11631549 | 0.71 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL10771095 | 0.69 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10EPHX2RAB9A | |
| SCHEMBL14557099 | 0.69 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114730902-A | Redox flow battery electrolytes with 2, 5-dimercapto-1, 3, 4-thiadiazole (\"DMTD\") and derivatives thereof | 路博润公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114401949-A | 2, 5-dimercapto-1, 3, 4-thiadiazole ('DMTD') derivatives | 路博润公司 | 2022-04-26 | — | — | CN | disclosed |
| US-8623111-B2 | Methods for creating a moist top dressing material and products related thereto | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120234219-A1 | Sand Based Fungicides | Board of Regents of Michigan State University | 2012-09-20 | — | — | US | disclosed |
| US-8202343-B2 | Sand based fungicides | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2012-06-19 | — | — | US | disclosed |
| US-8028928-B2 | Spreader apparatus for sand based formulations | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090181849-A1 | Agricultural chemical containing top dressing composition and process for use thereof | MICHIGAN STATE UNIVERSITY | 2009-07-16 | — | — | US | disclosed |
| US-20090151243-A1 | Spreader apparatus for sand based formulations | MICHIGAN STATE UNIVERSITY | 2009-06-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4861787-A | Nematicidal compositions | CIBA-GEIGY CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| US-4826992-A | MICROBIOCIDE INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0263066-A2 | 2-Mercapto-oxadiazole and -thiadiazole derivatives, process for their preparation and nematicides containing them | CIBA-GEIGY AG (CH) | 1988-04-06 | — | — | EP | disclosed |
| US-4716232-A | 1-(vinyl phosphonate adduct) pyrazolidinones | ELI LILLY AND COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203723-A1 | 2,3-(dihydro)bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | KDM4E 3077/4885ALDH1A1 2976/4885HSD17B10 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.